ASCENDIS PHARMA A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 122.8 USD | -1.00% |
|
-7.76% | -2.50% |
| May. 16 | Morgan Stanley Adjusts Ascendis Pharma Price Target to $140 From $116, Maintains Equal Weight Rating | MT |
| May. 14 | US Equity Markets Close Higher Tuesday as Producer Prices Rise | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
Calendar
2024-08-28
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
113
EUR
Average target price
168.6
EUR
Spread / Average Target
+49.25%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -2.50% | 7.04B | |
| +8.29% | 114B | |
| +10.21% | 104B | |
| +0.64% | 22.28B | |
| -11.90% | 22.41B | |
| -4.73% | 19.07B | |
| -37.36% | 18B | |
| -5.17% | 17.89B | |
| +7.70% | 14.28B | |
| +37.65% | 12.55B |
- Stock Market
- Equities
- ASND Stock
- News Ascendis Pharma A/S
- Wedbush Lowers Ascendis Pharma's Price Target to $186 From $195 After Model Adjustments, Keeps Outperform Rating
